Roche Holding AG (SWX:ROP) entered into a definitive merger agreement to acquire PathAI, Inc. for $1.1 billion on May 7, 2026. Under the terms of the agreement, Roche will pay a purchase price of $750 million upfront and additional milestone payments of up to $300 million. The acquired entity will become part of the Diagnostics division.
The transaction is subject to customary closing conditions, including antitrust and regulatory approvals. The closing of the transaction is currently expected in the second half of the year.
The team of Latham & Watkins LLP led by Luke Bergstrom, Stephen Ranere, Hoffman, Grace Lee, Julie Crisp, Deborah Hinck, Patrick English, Stephanie Adams, Paul Rosen, Aaron Amundson and Erin Brown Jones acted as a legal advisor to PathAI. The team of Davis Polk & Wardwell led by Marc O. Williams, Jack Gordge, Howard Shelanski, Frances Dethmers, Michael Mollerus, David R. Bauer, Samantha Lefland, Veronica M. Wissel and Joseph S. Brown acted as a legal advisor to Roche Holding AG.
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
